{
    "hands_on_practices": [
        {
            "introduction": "The journey of developing a gene therapy begins with the design of the delivery vehicle. For many ocular applications, the adeno-associated virus (AAV) is the vector of choice, but its primary limitation is a finite packaging capacity. This exercise provides hands-on practice in calculating the available \"cargo space\" for a therapeutic gene, a crucial first step that determines whether a gene of interest can be delivered using this platform .",
            "id": "4676317",
            "problem": "You are designing a retinal gene augmentation vector using Adeno-associated virus (AAV) for a loss-of-function inherited retinal disorder. The AAV genome that is packaged is defined from inverted terminal repeat (ITR) to ITR. Adopt the following foundational principles: the Central Dogma of molecular biology implies that a coding sequence must be fully contained in the vector to be expressed; and, for AAV vectors, efficient packaging requires that the total nucleotide content from ITR to ITR does not exceed the packaging limit. Assume linear additivity of sequence lengths across all vector components and ignore any non-sequence packaging overhead.\n\nThe vector components are: a promoter of length $0.5$ kb, a coding sequence of unknown length $L_{\\mathrm{cds}}$ kb, a polyadenylation signal (polyA) of length $0.2$ kb, and two inverted terminal repeats (ITRs) of length $0.29$ kb each. The AAV packaging limit is $4.7$ kb.\n\nUsing only these principles and data, determine the maximum allowable coding sequence length $L_{\\mathrm{cds}}$ (in kilobases) such that the total packaged genome length does not exceed the limit. Then, briefly explain in words how inclusion of additional regulatory elements (for example, introns, enhancers, or post-transcriptional elements) of total length $r$ kb would alter this maximum.\n\nExpress your final numerical answer for the maximum allowable coding sequence length in kilobases (kb), rounded to three significant figures.",
            "solution": "The problem is deemed valid as it is scientifically grounded in the principles of molecular biology and viral vector design, is well-posed with sufficient and consistent data, and is formulated objectively.\n\nThe problem requires the determination of the maximum allowable length for a coding sequence ($L_{\\mathrm{cds}}$) to be packaged within an Adeno-associated virus (AAV) vector, given constraints on the total genome size.\n\nFirst, we define the total length of the single-stranded DNA genome to be packaged, denoted as $L_{\\mathrm{total}}$. The problem states this genome is defined from Inverted Terminal Repeat (ITR) to ITR. In standard AAV vector biology, this refers to the entire nucleic acid molecule that is encapsulated, which includes both ITRs and all sequences situated between them. The problem specifies that we assume linear additivity of the lengths of all vector components. The components are the promoter, the coding sequence (CDS), the polyadenylation signal (polyA), and two ITRs.\n\nThe total length is therefore the sum of the lengths of these individual components:\n$$L_{\\mathrm{total}} = L_{\\mathrm{promoter}} + L_{\\mathrm{cds}} + L_{\\mathrm{polyA}} + 2 \\times L_{\\mathrm{ITR}}$$\n\nThe givens are:\n-   Promoter length, $L_{\\mathrm{promoter}} = 0.5$ kb\n-   Polyadenylation signal length, $L_{\\mathrm{polyA}} = 0.2$ kb\n-   Inverted terminal repeat length, $L_{\\mathrm{ITR}} = 0.29$ kb\n-   The AAV packaging limit, $L_{\\mathrm{limit}} = 4.7$ kb\n\nThe fundamental constraint is that the total length of the packaged genome cannot exceed the packaging limit:\n$$L_{\\mathrm{total}} \\le L_{\\mathrm{limit}}$$\n\nSubstituting the expression for $L_{\\mathrm{total}}$ into the inequality, we get:\n$$L_{\\mathrm{promoter}} + L_{\\mathrm{cds}} + L_{\\mathrm{polyA}} + 2 \\times L_{\\mathrm{ITR}} \\le L_{\\mathrm{limit}}$$\n\nTo find the maximum allowable coding sequence length, which we will denote as $L_{\\mathrm{cds, max}}$, we consider the case where the total length is exactly equal to the packaging limit. We can then rearrange the inequality to solve for $L_{\\mathrm{cds}}$:\n$$L_{\\mathrm{cds}} \\le L_{\\mathrm{limit}} - L_{\\mathrm{promoter}} - L_{\\mathrm{polyA}} - 2 \\times L_{\\mathrm{ITR}}$$\nThus, the maximum length is:\n$$L_{\\mathrm{cds, max}} = L_{\\mathrm{limit}} - L_{\\mathrm{promoter}} - L_{\\mathrm{polyA}} - 2 \\times L_{\\mathrm{ITR}}$$\n\nNow, we substitute the given numerical values into this equation. All lengths are in kilobases (kb).\n$$L_{\\mathrm{cds, max}} = 4.7 - 0.5 - 0.2 - 2 \\times (0.29)$$\nFirst, we calculate the total length contributed by the two ITRs:\n$$2 \\times 0.29 = 0.58 \\text{ kb}$$\nNow, substitute this back into the equation for $L_{\\mathrm{cds, max}}$:\n$$L_{\\mathrm{cds, max}} = 4.7 - 0.5 - 0.2 - 0.58$$\nSumming the lengths of the non-CDS components:\n$$0.5 + 0.2 + 0.58 = 1.28 \\text{ kb}$$\nFinally, subtracting this sum from the packaging limit:\n$$L_{\\mathrm{cds, max}} = 4.7 - 1.28 = 3.42 \\text{ kb}$$\nThe problem requires the answer to be rounded to three significant figures. The calculated value of $3.42$ already has three significant figures.\n\nFor the second part of the question, we are asked to explain how the inclusion of additional regulatory elements of total length $r$ kb would alter this maximum. According to the principle of linear additivity of sequence lengths, these additional elements would occupy space within the packaged genome. The total length of all non-CDS components would increase by $r$. The new equation for the maximum CDS length, let's call it $L'_{\\mathrm{cds, max}}$, would be:\n$$L'_{\\mathrm{cds, max}} = L_{\\mathrm{limit}} - (L_{\\mathrm{promoter}} + L_{\\mathrm{polyA}} + 2 \\times L_{\\mathrm{ITR}} + r)$$\nThis can be expressed in terms of the original maximum length:\n$$L'_{\\mathrm{cds, max}} = (L_{\\mathrm{limit}} - L_{\\mathrm{promoter}} - L_{\\mathrm{polyA}} - 2 \\times L_{\\mathrm{ITR}}) - r = L_{\\mathrm{cds, max}} - r$$\nTherefore, including additional regulatory elements of total length $r$ kb would directly reduce the maximum allowable coding sequence length by an amount equal to $r$. Each kilobase of sequence added for regulatory purposes must be subtracted from the available capacity for the coding sequence, as the total packaging limit is a strict physical constraint of the AAV capsid.",
            "answer": "$$\\boxed{3.42}$$"
        },
        {
            "introduction": "After designing a vector, the next challenge is ensuring its effective delivery from the syringe to the target retinal cells. This practice bridges the gap between the macroscopic administered dose, measured in total vector genomes, and the microscopic reality at the cellular level . By calculating the average vector genomes per cell, you will explore the concept of Multiplicity of Infection (MOI) and the statistical nature of vector-cell interactions.",
            "id": "4676281",
            "problem": "Adeno-Associated Virus (AAV) vector-mediated subretinal gene delivery aims to place therapeutic deoxyribonucleic acid (DNA) near target photoreceptors, leveraging the Central Dogma of molecular biology (DNA to ribonucleic acid (RNA) to protein) and the principle that the number of vector genomes is conserved during delivery, subject to physical distribution and biological uptake. Consider an advanced subretinal injection protocol in a human eye in which a bleb is raised that covers $20\\%$ of the retinal area. The dose instilled into the bleb is $3\\times 10^{11}$ vector genomes ($\\mathrm{vg}$), and the estimated number of photoreceptors contained within the bleb is $1.5\\times 10^{7}$ cells. Assume, for the purpose of the calculation, ideal uniform distribution of vector genomes throughout the bleb volume and that the vast majority of the dose remains confined within the bleb.\n\nUsing conservation of particle number and without invoking any pre-derived shortcut formula, derive from first principles the vector genomes per cell delivered to photoreceptors within the bleb. Then, interpret how this quantity relates to the concept of Multiplicity of Infection (MOI), defined as the ratio of infectious units to target cells, under a Poisson arrival model for particleâ€“cell encounters. Clearly state the assumptions under which vector genomes per cell can approximate the MOI parameter and articulate at least three realistic biological or physical factors in subretinal delivery that would cause deviations between vector genomes per cell and true MOI for photoreceptors.\n\nRound your final numerical answer for the vector genomes per cell to three significant figures and express it as a dimensionless number (no units). Do not provide an inequality or an equation as the final answer; provide a single real-valued number only.",
            "solution": "The fundamental base for the calculation is conservation of particle number, together with the definition of average loading per target under uniform distribution. If a total of $N_{\\mathrm{vg}}$ vector genomes are confined to a domain containing $N_{\\mathrm{cells}}$ target cells, and the distribution is uniform such that each cell samples the same expected number of genomes, then the expected vector genomes per cell $G$ satisfies\n$$\nG = \\frac{N_{\\mathrm{vg}}}{N_{\\mathrm{cells}}}.\n$$\nThis relation does not assume infectivity, binding, or productive entry; it is a purely physical average of genome count per target cell based on uniform mixing within the bleb.\n\nIn the present scenario, the dose instilled into the bleb is $N_{\\mathrm{vg}} = 3\\times 10^{11}$ and the number of photoreceptors within the bleb is $N_{\\mathrm{cells}} = 1.5\\times 10^{7}$. Substituting these values,\n$$\nG = \\frac{3\\times 10^{11}}{1.5\\times 10^{7}}.\n$$\nWe simplify by dividing coefficients and exponents of $10$:\n$$\nG = \\left(\\frac{3}{1.5}\\right)\\times 10^{11-7} = 2\\times 10^{4}.\n$$\nRounded to three significant figures, this remains $2.00\\times 10^{4}$.\n\nWe now discuss how $G$ relates to Multiplicity of Infection (MOI). Multiplicity of Infection (MOI) is defined as the ratio of infectious units (particles that successfully initiate a productive transduction) to the number of target cells. Under a Poisson arrival model, the number of productive infection events per cell is modeled as a Poisson random variable with parameter $\\lambda$, where\n$$\n\\lambda = \\alpha\\,G,\n$$\nand $\\alpha \\in (0,1)$ represents the effective fraction of vector genomes that are infectious and result in productive entry and expression in a target photoreceptor (this parameter encapsulates binding probability, entry efficiency, nuclear trafficking, uncoating, and transcription/translation competence). The probability that a given cell receives at least one productive infectious event is then\n$$\nP(\\text{at least one productive event}) = 1 - \\exp(-\\lambda) = 1 - \\exp(-\\alpha\\,G).\n$$\nUnder the assumptions that (i) distribution within the bleb is uniform, (ii) essentially all vector genomes remain confined to the bleb, and (iii) the fraction $\\alpha$ is approximately constant across cells in the bleb, the vector genomes per cell $G$ can serve as a proportional surrogate for the MOI parameter $\\lambda$ up to the factor $\\alpha$.\n\nRealistic factors that cause deviations between the physically computed $G$ and the true MOI for photoreceptors include:\n- Nonuniform spatial distribution within the bleb driven by local convection, diffusion barriers, and microanatomy, leading to cell-to-cell variability in exposure, meaning $G$ is not homogeneous across cells.\n- Binding and uptake differences across cell types and within photoreceptors due to receptor tropism, extracellular matrix composition, and outer segment geometry, which alter $\\alpha$ and thus decouple $G$ from $\\lambda$.\n- Vector loss mechanisms such as backflow, clearance into the choroid, interactions with immune components, or adsorption to the Retinal Pigment Epithelium (RPE), reducing the fraction of genomes available to photoreceptors and lowering $\\alpha$.\n- Intracellular barriers affecting productive transduction (endosomal escape, nuclear entry, second-strand synthesis for certain AAV serotypes), further decreasing the effective infectious fraction.\n- Temporal dynamics of vector distribution and photoreceptor turnover of endocytosed particles, which can render a single time-point $G$ an imperfect predictor of integrated MOI.\n\nThus, while $G = 2.00\\times 10^{4}$ provides the expected vector genomes per photoreceptor under uniform distribution, its interpretation as MOI requires specifying $\\alpha$ and acknowledging deviations from idealized assumptions. The numerical computation itself is purely the ratio of total vector genomes to the number of cells within the bleb.\n\nFinally, the rounded value to three significant figures is $2.00\\times 10^{4}$, expressed as a dimensionless number.",
            "answer": "$$\\boxed{2.00 \\times 10^{4}}$$"
        },
        {
            "introduction": "The ultimate goal of gene editing is to achieve a therapeutic effect by correcting a sufficient number of cells. This final exercise builds directly on the concept of vector delivery by using a powerful probabilistic model to predict the fraction of successfully edited cells . You will combine the Poisson statistics of vector distribution with the intrinsic probability of successful homology-directed repair (HDR) to create a quantitative framework for estimating therapeutic efficacy.",
            "id": "4676326",
            "problem": "A clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) gene editing experiment is performed in retinal photoreceptors using adeno-associated virus (AAV) delivery to correct a pathogenic allele via homology-directed repair (HDR). Empirically, the number of AAV vector genomes per cell is well modeled by a Poisson random variable with mean $\\lambda = 1.2$. Assume that each delivered vector genome independently initiates one HDR integration attempt, and that each attempt results in a successful HDR event with probability $p = 0.01$. A cell is considered phenotypically corrected if it experiences at least one successful HDR event.\n\nStarting from the definition of the Poisson distribution and the law of total probability, derive an expression for the expected fraction of corrected cells in terms of $\\lambda$ and $p$, and then evaluate it for $\\lambda = 1.2$ and $p = 0.01$. Express your final result as a unitless decimal fraction and round your answer to four significant figures.",
            "solution": "The problem is valid as it is scientifically grounded, well-posed, and objective. It provides a complete set of parameters and definitions to solve a standard biostatistics problem involving compound probability distributions.\n\nThe objective is to derive an expression for the expected fraction of corrected cells, which is equivalent to the probability that a randomly-selected cell is corrected. Let this probability be denoted by $P(C)$.\n\nLet $N$ be the random variable representing the number of adeno-associated virus (AAV) vector genomes that enter a single cell. According to the problem statement, $N$ follows a Poisson distribution with mean $\\lambda$. The probability mass function (PMF) of $N$ is given by:\n$$P(N=n) = \\frac{\\lambda^n \\exp(-\\lambda)}{n!}, \\quad \\text{for } n = 0, 1, 2, \\dots$$\n\nA cell is considered phenotypically corrected if it experiences at least one successful homology-directed repair (HDR) event. Let $C$ be the event that a cell is corrected. The probability of this event, $P(C)$, can be found using the law of total probability, by conditioning on the number of vector genomes $N$:\n$$P(C) = \\sum_{n=0}^{\\infty} P(C | N=n) P(N=n)$$\nHere, $P(C | N=n)$ is the probability that a cell is corrected given that it contains exactly $n$ vector genomes.\n\nWe are given that each vector genome independently initiates an HDR attempt with a success probability of $p$. For a cell with $n$ vector genomes, this constitutes a sequence of $n$ independent Bernoulli trials. The number of successful HDR events, let's call it $S_n$, follows a binomial distribution with parameters $n$ and $p$, i.e., $S_n \\sim \\text{Binomial}(n,p)$.\n\nThe cell is corrected if $S_n \\ge 1$. It is more convenient to calculate the probability of the complementary event, i.e., that there are zero successful HDR events ($S_n=0$). The probability of zero successes in $n$ trials is:\n$$P(S_n = 0) = \\binom{n}{0} p^0 (1-p)^{n-0} = (1-p)^n$$\nTherefore, the conditional probability of a cell being corrected, given $n$ vector genomes, is:\n$$P(C | N=n) = P(S_n \\ge 1) = 1 - P(S_n=0) = 1 - (1-p)^n$$\nNote that for the case $n=0$, this expression correctly yields $P(C | N=0) = 1 - (1-p)^0 = 1 - 1 = 0$, as a cell with no vector genomes cannot be corrected.\n\nNow, we substitute the expressions for $P(N=n)$ and $P(C | N=n)$ back into the law of total probability:\n$$P(C) = \\sum_{n=0}^{\\infty} \\left[1 - (1-p)^n\\right] \\frac{\\lambda^n \\exp(-\\lambda)}{n!}$$\nWe can split this summation into two parts:\n$$P(C) = \\sum_{n=0}^{\\infty} \\frac{\\lambda^n \\exp(-\\lambda)}{n!} - \\sum_{n=0}^{\\infty} (1-p)^n \\frac{\\lambda^n \\exp(-\\lambda)}{n!}$$\nThe first term is the sum of the PMF of the Poisson distribution over its entire support, which is equal to $1$:\n$$\\sum_{n=0}^{\\infty} \\frac{\\lambda^n \\exp(-\\lambda)}{n!} = \\exp(-\\lambda) \\sum_{n=0}^{\\infty} \\frac{\\lambda^n}{n!} = \\exp(-\\lambda) \\exp(\\lambda) = 1$$\nFor the second term, we can factor out $\\exp(-\\lambda)$ and combine the terms raised to the power of $n$:\n$$\\sum_{n=0}^{\\infty} (1-p)^n \\frac{\\lambda^n \\exp(-\\lambda)}{n!} = \\exp(-\\lambda) \\sum_{n=0}^{\\infty} \\frac{[\\lambda(1-p)]^n}{n!}$$\nThe summation is the Taylor series expansion of the exponential function $\\exp(x) = \\sum_{k=0}^{\\infty} \\frac{x^k}{k!}$, with $x = \\lambda(1-p)$. Thus, the second term simplifies to:\n$$\\exp(-\\lambda) \\exp(\\lambda(1-p)) = \\exp(-\\lambda + \\lambda - \\lambda p) = \\exp(-\\lambda p)$$\nCombining the results for the two terms, we arrive at the final expression for the expected fraction of corrected cells:\n$$P(C) = 1 - \\exp(-\\lambda p)$$\nThis is the derived expression in terms of $\\lambda$ and $p$.\n\nWe are given the values $\\lambda = 1.2$ and $p = 0.01$. Substituting these into the expression:\n$$P(C) = 1 - \\exp(-(1.2)(0.01)) = 1 - \\exp(-0.012)$$\nNow, we evaluate this numerically:\n$$\\exp(-0.012) \\approx 0.988071505$$\n$$P(C) \\approx 1 - 0.988071505 = 0.011928495$$\nThe problem requires the answer to be rounded to four significant figures. The first significant figure is the first digit $1$. Counting four figures gives us $0.01192$. The fifth significant digit is $8$, which is greater than or equal to $5$, so we round up the last digit.\n$$P(C) \\approx 0.01193$$\nThis is the expected fraction of corrected cells.",
            "answer": "$$\\boxed{0.01193}$$"
        }
    ]
}